Physician profile
Kelli Roth
NPI 1023898244
$2,002.79
in general payments reported to CMS, 2019-2025
17 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $218 · 2024: $1,513 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.07 | 2023-2025 | |
| Incyte Corporation | $315.99 | 2023-2025 | Opzelura |
| Ucb, INC. | $273.36 | 2023-2024 | Bimzelx |
| Genzyme Corporation | $213.73 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $180.62 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $169.92 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $153.98 | 2024 | |
| Sun Pharmaceutical Industries INC. | $60.47 | 2023-2024 | Ilumya |
| Verrica Pharmaceuticals INC. | $44.35 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $41.88 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $33.48 | 2024-2025 | Zoryve |
| Pfizer INC. | $29.12 | 2024 | |
| Janssen Biotech, INC. | $26.93 | 2024 | Tremfya |
| Leo Pharma INC. | $21.50 | 2023 | Adbry |
| Lilly USA, LLC | $21.02 | 2024 | Olumiant, Taltz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $19.73 | 2025 | Immunocap |
| Organon LLC | $17.64 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.